Spark Investment Management’s Moleculin Biotech MBRX Stock Holding History

Spark Investment Management’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-8	Closed	-$124K	–	862
2016 Q2	$124K	Buy	+8	New	+$129K	0.01%	682

Other funds holding MBRX

ING Group Amsterdam, Netherlands $16.4B AUM 34.6% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AIM

Acrospire Investment Management Chicago, Illinois $33K AUM 23.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

WFG Advisors Dallas, Texas $442M AUM 12.46% 1-Year Est. Return

Spark Investment Management's MBRX Position: Q3 2016 in Review

Spark Investment Management sold out of Moleculin Biotech (MBRX) in Q3 2016, closing a stake of 8 shares — an estimated $124K sold.

Spark Investment Management first reported a position in MBRX in Q2 2016 and held it in 1 quarter. The position peaked at $124K in Q2 2016. 5 funds tracked by Wall St. Rank hold MBRX as of Q3 2016.

Spark Investment Management reported no remaining Moleculin Biotech position as of Q3 2016 after selling out during the quarter.
Spark Investment Management sold 8 Moleculin Biotech shares in Q3 2016, an estimated $124K.
Spark Investment Management first reported a position in Moleculin Biotech in Q2 2016 and held it in 1 quarter.
Spark Investment Management's Moleculin Biotech position peaked at $124K in Q2 2016.
5 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2016.

Based on Spark Investment Management's 13F filing for Q3 2016, filed 10 Nov 2016.